A cationic TAT peptide inhibits herpes simplex virus type 1 infection of human corneal epithelial cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 6, 2010, Pages 541-547

  Larsen, Inna V ^a   Brandt, Curtis R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; BETA GALACTOSIDASE; PEPTIDE TAT CD 0; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG TOXICITY; ENZYME ACTIVITY; EPITHELIUM CELL; EXPERIMENTAL INFECTION; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REDUCTION; VIRUS ENTRY; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BETA-GALACTOSIDASE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM, CORNEAL; GENE PRODUCTS, TAT; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; PEPTIDE FRAGMENTS; PEPTIDES; TIME FACTORS; TOXICITY TESTS; VIRUS REPLICATION;

EID: 78649712611     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0076     Document Type: Article

References (24)

1. Whitley, R.J. Herpes simplex viruses. In: Fields, B.N., Knipe, D.M., and Howley, P.M., eds. Fields Virology, 3rd ed., Vol. 2. Philadelphia: Lippincott-Raven; 1996; pp. 2297-2342.
2. Liesegang, T.J. Epidemiology and natural history of ocular herpes simplex virus infection in Rochester, Minnesota, 1950-1982. Trans. Am. Ophthalmol. Soc. 86:688-724, 1998.
3. Liesegang, T.J. Herpes simplex virus epidemiology and ocular importance. Cornea 20:1-13, 2001.
4. Wilhelmus, K.R., Gee, L., Hauck, W.W., et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 101:1883-1895, 1994
5. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N. Engl. J. Med. 339:300-306, 1998.
6. Brandt, C.R., Coakley, L.M., and Grau, D.R. A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. J. Virol. Methods 36:209-222, 1992.
7. Brandt, C.R., Spencer, B., Imesch, P., Garneau, M., and De-ziel, R. Evaluation of a peptidomimetic ribonucleotide re-ductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob. Agents Chemother. 40:1078-1084, 1996.
8. Bultmann, H., Busse, J.S., and Brandt, C.R. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 75:2634-2645, 2001.
9. Bultmann, H., and Brandt, C.R. Peptides containing membrane-transiting motifs inhibit virus entry. J. Biol. Chem. 277:36018-36023, 2002.
10. Jones, J.C., Turpin, E.A., Bultmann, H., Brandt, C.R., and Schultz-Cherry, S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80:11960-11967, 2006.
11. Bultmann, H., Teuton, J., and Brandt, C.R. Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain. An-timicrob. Agents Chemother. 51:1596-1607, 2007.
12. Akkarawongsa, R., Porcaro, N.E., Case, G., Kolb, A.W., and Brandt, C.R. Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. An-timicrob. Agents Chemother. 53:987-996, 2009.
13. Altmann, S.E., Jones, J.C., Schultz-Cherry, S., and Brandt, C.R. Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide. Virology 388:248-259, 2009.
14. Akkarawongsa, R., Cullinan, A.E., Zinkel, A., Clarin, J., and Brandt, C.R. Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry. J. Ocular Pharm. Ther. 22:279-289, 2006.
15. Brandt, C.R., Akkarawongsa, R., Altmann, S., et al. Evaluation of a y-defensin in a murine model of herpes simplex virus type 1 keratitis. Invest. Ophthalmol. Vis. Sci. 48:5118-5124, 2007.
16. Araki-Sasaki, K., Ohashi, Y., Sasabe, T., et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci. 36:614-621, 1995.
17. Goldstein, D.J., and Weller, S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62:196-205, 1988.
18. Grau, D.R., Visalli, R.J., and Brandt, C.R. Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence. Invest. Ophthalmol. Vis. Sci. 30:2474-2480, 1989.
19. Visalli, R.J., and Brandt, C.R. The HSV-1 UL45 18kDa gene product is a true late protein and a component of the virion. Virus Res. 29:167-178, 1993.
20. Segel, I.H. Biochemical Calculations. 2nd ed. New York: John Wiley & Sons; 1976.
21. Tyagi, M., Rusnati, M., Presta, M., and Giacca, M. Inter-nalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261, 2001.
22. Ziegler, A., and Seelig, J. Interaction of the protein trans-duction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys. J. 86:252-263, 2004.
23. Spear, P.G., and Longnecker, R. Herpesvirus entry: an update. J. Virol. 77:10179-10185, 2003.
24. Richard, J.P., Melikov, K., Vives, E., et al. Cell penetrating peptides. J. Biol. Chem. 278:585-590, 2003.